Emergent Biosolutions (EBS) Given News Impact Rating of 0.11
Media stories about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Emergent Biosolutions earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.490881097817 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s analysis:
- Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From … – GlobeNewswire (press release) (globenewswire.com)
- Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent … – PR Newswire (press release) (prnewswire.com)
- BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector (EBS) (markets.businessinsider.com)
- Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector (finance.yahoo.com)
- Emergent BioSolutions Completes Acquisition Of Raxibacumab, An FDA-Approved Anthrax Monoclonal Antibody, From GlaxoSmithKline (biospace.com)
Shares of Emergent Biosolutions (NYSE:EBS) traded down 0.32% during midday trading on Thursday, hitting $40.43. The company had a trading volume of 105,726 shares. Emergent Biosolutions has a 12 month low of $24.47 and a 12 month high of $41.46. The company has a market capitalization of $1.67 billion, a PE ratio of 25.75 and a beta of 1.26. The company has a 50-day moving average of $37.58 and a 200-day moving average of $33.37.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.13). Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. During the same quarter last year, the company earned ($0.05) earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Analysts predict that Emergent Biosolutions will post $1.54 earnings per share for the current year.
A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reissued an “outperform” rating and set a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $45.00.
TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions (EBS) Given News Impact Rating of 0.11” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at http://www.mareainformativa.com/emergent-biosolutions-ebs-given-news-impact-rating-of-0-11/117479/.
In other news, Director Ronald Richard sold 22,415 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $40.00, for a total value of $896,600.00. Following the sale, the director now directly owns 24,676 shares in the company, valued at $987,040. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Fuad El-Hibri sold 25,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $40.50, for a total value of $1,012,500.00. Following the completion of the sale, the chairman now owns 1,555,216 shares in the company, valued at $62,986,248. The disclosure for this sale can be found here. Insiders have sold 230,227 shares of company stock worth $8,793,970 over the last 90 days. 16.50% of the stock is owned by insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.